Citation: | LIU Yun, LIU Ying, LIU Jiahui, WANG Lu, HOU Wenrui, LI Dianming. Clinical efficacy of afatinib in second-line treatment of advanced squamous cell carcinoma of the lung[J]. Chinese Journal of General Practice, 2024, 22(9): 1491-1495. doi: 10.16766/j.cnki.issn.1674-4152.003666 |
[1] |
赵皓, 齐学远, 王俊斌, 等. 外周血淋巴细胞亚群在非小细胞肺癌中的表达及意义[J]. 中华全科医学, 2023, 21(11): 1849-1851, 1981. doi: 10.16766/j.cnki.issn.1674-4152.003240
ZHAO H, QI X Y, WANG J B, et al. Expression and significance of peripheral blood lymphocyte subsets in non-small cell lung cancer[J]. Chinese Journal of General Practice, 2023, 21(11): 1849-1851, 1981. doi: 10.16766/j.cnki.issn.1674-4152.003240
|
[2] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
|
[3] |
于江泳, 武晓楠, 马俊玲, 等. 中国人群肺鳞癌患者免疫治疗疗效及不良反应观察[J]. 中国肺癌杂志, 2022, 25(7): 546-554.
YU J Y, WU X N, MA J L, et al. Clinical Observation of Immunotherapy Efficacy and Adverse Effects in Chinese Patients with Lung Squamous Cell Carcinoma[J]. Chinese Journal of Lung Cancer, 2022, 25(7): 546-554.
|
[4] |
MOOSAVI L, POLINENI R. Afatinib[M]. Treasure Island (FL): Stat Pearls Publishing, 2024.
|
[5] |
FREITES-MARTINEZ A, SANTANA N, ARIAS-SANTIAGO S, et al. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr (Engl Ed), 2021, 112(1): 90-92. doi: 10.1016/j.ad.2019.05.009
|
[6] |
况春丽, 李明, 郑泰浩. 阿帕替尼治疗晚期非小细胞肺癌疗效与安全性的Meta分析[J]. 中国现代医学杂志, 2021, 31(8): 70-77. doi: 10.3969/j.issn.1005-8982.2021.08.013
KUANG C L, L M, ZHENG T H. Meta-analysis of the efficacy and safety of apatinib in the treatment of advanced non-small cell lung cancer[J]. China Journal of Modern Medicine, 2021, 31(8): 70-77. doi: 10.3969/j.issn.1005-8982.2021.08.013
|
[7] |
BORGHAEI H, GETTINGER S, VOKES E E, et al. Five-year outcomes from the randomized, phase Ⅲ trials checkmate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J]. J Clin Oncol, 2021, 39(7): 723-733. doi: 10.1200/JCO.20.01605
|
[8] |
GOSS G D, COBO M, LU S, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: final analysis of the randomised phase 3 LUX-Lung 8 trial[J]. EClinicalMedicine, 2021, 37: 100940. DOI: 10.1016/j.eclinm.2021.100940.
|
[9] |
张静, 张敏, 路平. 口腔鳞状细胞癌治疗研究进展[J]. 新乡医学院学报, 2024, 41(2): 180-186.
ZHANG J, ZHANG M, LU P. Research progress in the treatment of oral squamous cell carcinoma[J]. Journal of Xinxiang Medical University, 2024, 41(2): 180-186.
|
[10] |
SANTOS E S, HART L. Advanced squamous cell carcinoma of the lung: current treatment approaches and the role of afatinib[J]. Onco Targets Ther, 2020, 13: 9305-9321. doi: 10.2147/OTT.S250446
|
[11] |
CHEN Y Y, CHANG S C, CHANG C Y, et al. Real-world effectiveness of second-line afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naive patients[J]. BMC Cancer, 2021, 21(1): 1225. DOI: 10.1186/s12885-021-08920-3.
|
[12] |
KIM E S, KISH J K, CSEH A, et al. Second-line afatinib or chemotherapy following immunochemotherapy for the treatment of metastatic, squamous cell carcinoma of the lung: real-world effectiveness and safety from a multisite retrospective chart review in the USA[J]. Clin Lung Cancer, 2021, 22(4): 292-300. doi: 10.1016/j.cllc.2021.02.006
|
[13] |
王守正. TP53基因作为非小细胞肺癌靶向及免疫治疗疗效预测指标的价值及机制[D]. 北京: 北京协和医学院, 2022.
WANG S Z. The value and mechanism of TP53 gene as a predictor of targeting and immunotherapy efficacy in non-small cell lung cancer[D]. Beijing: Peking Union Medical College, 2022.
|
[14] |
陈建军. DDR2和IFITM1在非小细胞肺癌中的表达及临床意义[J]. 现代肿瘤医学, 2020, 28(10): 1677-1681. doi: 10.3969/j.issn.1672-4992.2020.10.015
CHEN J J. The expressions and clinical significances of DDR2 and IFITM1 in non-small cell lung cancer[J]. Journal of Modern Oncology, 2020, 28(10): 1677-1681. doi: 10.3969/j.issn.1672-4992.2020.10.015
|
[15] |
陈利娟, 穆晓倩, 刘杰, 等. PTEN通过磷脂酰肌醇-3-激酶/蛋白激酶B信号通路对非小细胞肺癌顺铂敏感性的影响[J]. 新乡医学院学报, 2020, 37(6): 501-508.
CHEN L J, MU X Q, LIU J, et al. Effect of PTEN on the sensitivity of non-small cell lung cancer to cisplatin through the phosphatidylinositol-3-kinase/protein kinase B signaling pathway[J]. Journal of Xinxiang Medical University, 2020, 37(6): 501-508.
|
[16] |
AJIMIZU H, OZASA H, SATO S, et al. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer[J]. Sci Rep, 2021, 11(1): 23677-23677. DOI: 10.1038/s41598-021-03139-5.
|
[17] |
WU K, WANG J, ZHAO L, et al. The prognosis of non-small cell lung cancer combined with chronic obstructive pulmonary disease: a systematic review and meta-analysis[J]. Clin Respir J, 2020, 14(4): 389-396. doi: 10.1111/crj.13144
|